Cancer Profiling Market Intelligence Report Covers Trends, Segments And Regional Growth

The cancer profiling market is emerging as a rapidly expanding sector within healthcare, driven by advances in precision medicine and diagnostic technologies. As the demand for more personalized and effective cancer treatments continues to rise, the market is set to experience significant growth over the coming years. Let's explore the market's size, key players, future trends, and segmentation details to gain a comprehensive understanding of this vital industry.

Projected Market Size and Expansion of the Cancer Profiling Industry
The cancer profiling market is anticipated to grow substantially, reaching a value of $25.62 billion by 2030. This expansion is expected to occur at an impressive compound annual growth rate (CAGR) of 11.3%. Several factors contribute to this robust growth outlook, such as the increasing adoption of precision medicine approaches, the broadening use of companion diagnostics, the rise of liquid biopsy technologies, growing investments in oncology diagnostics, and the integration of profiling techniques into standard clinical workflows. Key trends shaping the market during this period include the widespread use of next-generation sequencing (NGS)-based cancer profiling, the expansion of comprehensive genomic panels, the incorporation of artificial intelligence (AI) for data interpretation, the development of personalized oncology diagnostics, and a stronger focus on early molecular detection.

The cancer profiling market size has grown rapidly in recent years. It will grow from $15 billion in 2025 to $16.67 billion in 2026 at a compound annual growth rate (CAGR) of 11.1%. The growth in the historic period can be attributed to increasing cancer incidence rates, expansion of molecular diagnostics laboratories, early adoption of genomic testing in oncology, growth in research-based cancer profiling, rising availability of diagnostic platforms.

Download a free sample of the cancer profiling market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9912&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Leading Companies Commanding the Cancer Profiling Market
The cancer profiling field is dominated by a number of influential companies that play significant roles in advancing diagnostic capabilities. Notable players include Illumina Inc., Qiagen NV, NeoGenomics Inc., Sysmex Corporation, HTG Molecular Diagnostics Inc., Caris Life Sciences, NanoString Technologies Inc., Guardant Health Inc., Foundation Medicine Inc., Roche Diagnostics Corporation, F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Genscript Biotech Corporation, Tempus Labs Inc., Hologic Inc., Predictive Oncology Inc., Abbott Laboratories, Agilent Technologies Inc., PerkinElmer Inc., Siemens Healthineers, Genomic Health Inc., Natera Inc., ArcherDX Inc., Personal Genome Diagnostics Inc., Enzo Biochem Inc., Cancer Genetics Inc., OncoDNA SA, Ribomed Biotechnologies Inc., Biocartis Group NV, N-of-One Inc., Cynvenio Biosystems Inc., Inivata Ltd., Burning Rock Biotech Limited, PathAI Inc., GENEWIZ Inc., Genoptix Inc., OmniSeq Comprehensive, Resolution Bioscience, and OncoCyte Corporation.

A notable industry event includes Agilent Technologies' acquisition of Avida Biomed Inc. in January 2023, aimed at bolstering its molecular biology tools and synthetic biology technology offerings. This move highlights a trend toward strategic consolidations to accelerate innovation in cancer profiling.

View the full cancer profiling market report:
https://www.thebusinessresearchcompany.com/report/cancer-profiling-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Emerging Advances and Future Trends in Cancer Profiling
The cancer profiling market is witnessing a strong push toward technological innovation, especially with the development of combined sequencing assays. Companies are focusing on assays that perform simultaneous whole-exome sequencing (WES) and whole-transcriptome sequencing (WTS), delivering more comprehensive and clinically actionable molecular diagnostics. Unlike traditional NGS tests that often require multiple separate assays or limited gene panels, these integrated workflows analyze DNA and RNA together, enabling detection of various genomic alterations along with gene expression or fusion events.

For instance, in November 2024, Caris Life Sciences, a precision medicine company based in the US, received FDA approval for MI Cancer Seek, an NGS in vitro diagnostic test that performs WES and WTS simultaneously. This assay uses total nucleic acid (TNA) extracted from formalin-fixed paraffin-embedded (FFPE) tumor tissue to detect single-nucleotide variants, insertions and deletions across 228 genes, as well as microsatellite instability (MSI), tumor mutational burden (TMB), and copy-number amplifications in breast cancer. By combining DNA and RNA profiling in one test, this method conserves tissue, provides companion diagnostic indications across multiple tumor types, and speeds up therapy selection through a unified genomic analysis.

Detailed Segmentation of the Global Cancer Profiling Market
The report categorizes the cancer profiling market based on several key parameters to give a clear picture of its composition:

1) By Technology:
- Immunoassays
- Polymerase Chain Reaction (PCR)
- Next-Generation Sequencing (NGS)
- Microarrays
- In-Situ Hybridization

2) By Biomarker Type:
- Genomic Biomarkers
- Protein Biomarkers

3) By Cancer Type:
- Breast Cancer
- Lung Cancer
- Colorectal Cancer
- Prostate Cancer
- Melanoma
- Other Cancers

4) By Application:
- Research Applications
- Clinical Applications
- Diagnostics
- Prognostics
- Other Applications

Further breaking down the technology segment:

- Immunoassays include Enzyme-Linked Immunosorbent Assay (ELISA), Western Blotting, and Luminex xMAP Technology.
- PCR is subdivided into Quantitative PCR (qPCR), Digital PCR (dPCR), and Reverse Transcription PCR (RT-PCR).
- NGS encompasses Whole Genome Sequencing (WGS), Whole Exome Sequencing (WES), Targeted Sequencing, and RNA Sequencing (RNA-Seq).
- Microarrays cover DNA Microarrays, RNA Microarrays, and SNP Arrays.
- In-Situ Hybridization involves Fluorescence In-Situ Hybridization (FISH) and Chromogenic In-Situ Hybridization (CISH).

This detailed segmentation highlights the wide range of techniques and applications driving the precision and customization of cancer profiling, fueling ongoing growth and innovation in the market.

Our 2026 market reports now feature expanded strategic intelligence through market attractiveness scoring and analysis, total addressable market (TAM) analysis, company scoring matrix graphics and tables, Excel-based dashboards, market hotspots infographics, key technology and future trend analysis, along with updated graphics and tables.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.